Navigation Links
Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile

l outcome of the phase I trial has paved the way to move our novel TB vaccine forward. It is designed to function in a stand alone schedule, as well as in combination with previous exposure(s) to BCG or other closely related mycobacteria. It seems that our decision to combine our antigen with IC31™ has been a sound judgement on the base of our preclinical data”, explains Peter Andersen, Director of Vaccine Research and Development, SSI.

Intercell’s CSO, Alexander von Gabain, commented: “Our adjuvant IC31™ proved an outstanding profile to stimulate a strong T-cell immune response in humans as already previously seen in a variety of animal models. These results prove the scientific concept of our adjuvant and encourage a broad and commercial use of IC31™ in a variety of prophylactic and therapeutic vaccines.”

About tuberculosis

TB causes the death of two-three million people every year and one-third of the world’s population is infected by the bacteria Mycobacterium tuberculosis which makes this disease one of the most severe global health problems.

The Calmette (Bacillus Calmette-Guérin (BCG)) vaccine is a live vaccine that, when given to newborns, provides good protection against TB for 10-15 years. However, when the protective effect decreases, yet another BCG vaccination does not provide sufficient TB protection. Therefore, a new type of TB vaccine is needed to address the need of TB protection in the adult population.

About H1

H1 is a TB vaccine antigen in which two immuno dominant TB antigens (Ag85B and ESAT6) are fused together by recombinant technology and produced as a poly-protein.

About IC31TM

Adjuvants enhance the effectiveness of vaccines. Existing adjuvants on the market induce antibod
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 /PRNewswire/ ... that it will release its second quarter 2015 financial ... 6, 2015.   In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
(Date:7/30/2015)... , July 30, 2015  EP Global Communications, ... have recently contacted the Company about discussing EPGL,s ... early as Monday, August 3, 2015.  Novartis CEO ... saying that the coming electronic contact lens market ... over the next several years.  Novartis partnered with ...
(Date:7/30/2015)... , July 30, 2015  OncoGenex Pharmaceuticals, Inc. ... report its second quarter 2015 financial results on Thursday, ... call and live webcast at 4:30 p.m. Eastern Time ... programs and a general corporate update. ... Relations page of the OncoGenex website at www.oncogenex.com ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... NATICK, Mass., May 4, 2011 Boston Scientific ... several milestones in the adoption of its SpyGlass® ... July 2007.  The SpyGlass System guides visualization and ... the pancreatico-biliary system, including the hepatic ducts.  It ...
... 4, 2011 Volcano Corporation (NASDAQ: VOLC ), ... therapy guidance tools designed to enhance the treatment of coronary ... first quarter of 2011 increased 22 percent versus revenues in ... ended March 31, 2011, Volcano reported revenues of $81.0 million, ...
Cached Medicine Technology:Boston Scientific's SpyGlass® Direct Visualization System Achieves Global Utilization Milestones 2Boston Scientific's SpyGlass® Direct Visualization System Achieves Global Utilization Milestones 3Boston Scientific's SpyGlass® Direct Visualization System Achieves Global Utilization Milestones 4Boston Scientific's SpyGlass® Direct Visualization System Achieves Global Utilization Milestones 5Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability 2Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability 3Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability 4Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability 5Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability 6
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot and ... new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for ... commemorate introduction of this new type of sod, Super-Sod is giving away red Adirondack ...
(Date:7/31/2015)... ... 2015 , ... Ticket Down is a reliable source for authentic tickets for ... Park. The festival will end on Sunday, August 2nd. , Music ... Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment from ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... introduced its new store run by GoodThreads. The store can be accessed by ... and designs, many of which are customizable. The best part: whenever a product ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being ... meal, making July the most appropriate to be National Hot Dog Month. King Kullen ... the next cookout different than the ones in the past. Celebrate National Hot Dog ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... and the University of Pittsburgh Medical Center will be ... conjunction with the G20 Pittsburgh Summit Sept. 24-25. These ... how and why the "eds and meds" sector of ... region,s success. The Eds-Meds program will begin at ...
... RUTHERFORD, N.J., Aug. 28 As concerns ... soar, and sales and profits are being diverted outside ... to keep their Vectra(R) products, and the health and ... Through their Bloodhound(R) Technology, a unique track-and-trace barcode system, ...
... , , , MUMBAI, ... Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced ... with the U.S. Federal Trade Commission (FTC) and the Antitrust ... Hart-Scott-Rodino (HSR) Act waiting period in connection with the Tender ...
... ADD and more , FRIDAY, Aug. 28 (HealthDay News) -- ... appears that your "mind,s eye" acts like a spotlight to ... the right person. , Researchers from the Massachusetts Institute of ... for a specific tilted, colored bar among a field of ...
... , , Free ... Physician-Specific Information , , RICHMOND, Va., ... hospital discharges in Virginia. Virginia Health Information ... an updated, free, interactive online guide containing information on the ...
... , , , WASHINGTON, Aug. ... and firearm owners against greater government control of American society," says ... , "Seniors oppose Obama health care proposals at town ... period of economic difficulty because of concern about prospective Obama gun ...
Cached Medicine News:Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 2Health News:Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology 3Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 2Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 3Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2Health News:VHI Releases Consumer Guide to Obstetrical Services in Virginia 2Health News:Firearm Owners and Seniors Coalesce Against Obama Agenda, Says Gun Law Expert 2
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
... Disc Arthroplasty System consists of a two-part ... which is inserted into the disc space ... balloon is then injected with the flowable ... implant that conforms to the shape and ...
... Automated EIA Analyzer is an exceptional ... of complex microplate-based assays. The system's ... to busy laboratories. For low volume ... processing of assays with common features ...
... CP* the performance of the ADVIA Centaur ... Available in a benchtop model with a footprint ... cm), the ADVIA Centaur CP fits in anywhere. ... your lab with optimal productivity, speed and efficiency ...
Medicine Products: